Extrachromosomal circular DNAs in prostate adenocarcinoma: global characterizations and a novel prediction model
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Extrachromosomal circular DNA (eccDNA) amplifications in prostate adenocarcinoma (PRAD) were characterized. ZNF330 and PITPNM3 were identified as key genes, forming a risk model predicting prognosis and immunotherapy response in PRAD patients.
Area Of Science
- Genomics
- Cancer Biology
- Immunology
Background
- The role of extrachromosomal circular DNA (eccDNA) and focal amplifications in prostate adenocarcinoma (PRAD) remains unclear.
- This study aimed to characterize eccDNA and eccDNA-amplified key differentially expressed encoded genes (eKDEGs) in PRAD progression, immune response, and immunotherapy.
Purpose Of The Study
- To investigate the global characterization of eccDNA in PRAD.
- To identify and characterize eccDNA-amplified key differentially expressed encoded genes (eKDEGs) associated with PRAD prognosis, immune response, and immunotherapy.
- To develop a prognostic and predictive model for PRAD based on eKDEGs.
Main Methods
- Circular sequencing (Circular_seq) and TCGA-PRAD transcriptome data were used to identify eccDNA-amplified differentially expressed coding genes (eDEGs).
- Cox and Lasso regression analyses were employed to build risk models and identify PRAD prognostic eKDEGs.
- Immunological algorithms were used to quantify the immune microenvironment and assess immunotherapy response.
Main Results
- No significant differences in eccDNA size, type, or chromosomal distribution were found between PRAD and normal tissues.
- 4,290 differentially expressed eccDNAs and 1,981 amplified coding genes were identified, with 499 eDEGs analyzed.
- ZNF330 and PITPNM3 were identified as PRAD eKDEGs, forming a validated two-factor risk model associated with poor prognosis, altered immune infiltration, and reduced response to anti-CTLA-4/anti-PD-1 therapy.
Conclusions
- ZNF330 and PITPNM3 serve as potential prognostic markers for PRAD.
- The developed risk model accurately assesses PRAD patient survival, prognosis, and immunotherapy response.
- This research offers novel insights for PRAD immunotherapy strategies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.